Senate holds hearing on biosimilar agents with FDA director, some senators call for action

The Subcommittee on Primary Health and Retirement Security met on Thursday, September 17 for a hearing on the implementation of biosimilar agents with Janet Woodcock, MD, director of the Center for Drug Evaluation and Research at the FDA, and among other questions about interchangeability and safety, some senators questioned the lack of action in the issuance of guidance documents. The hearing, moderated by Sen. William Cassidy, MD, (R-La.) included Woodcock as its only witness.